

Multimodal analgesia reduces opioid requirements in trauma patients with rib fractures

Shakira W. Burton, MD, Christina Riojas, MD, Gail Gesin, PharmD, Charlotte B. Smith, BS, Vashti Bandy, MD, Ronald Sing, MD, Tamar Roomian, MS, MPH, Meghan K. Wally, MSPH, PhD, Cynthia W. Lauer, MD, and PRIMUM Group Charlotte, North Carolina

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Surgeons and American Association for the Surgery of Trauma. The American College of Surgeons is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Category 1 Credits™

The American College of Surgeons designates this journal-based activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Of the AMA PRA Category 1 Credit™ listed above, a maximum of 1.00 credit meets the requirements for self-assessment.



AMERICAN COLLEGE OF SURGEONS
Inspiring Quality.
Highest Standards, Better Outcomes



AMERICAN COLLEGE OF SURGEONS
DIVISION OF EDUCATION

Objectives

After reading the featured articles published in the *Journal of Trauma and Acute Care Surgery*, participants should be able to demonstrate increased understanding of the material specific to the article. Objectives for each article are featured at the beginning of each article and online. Test questions are at the end of the article, with a critique and specific location in the article referencing the question topic.

Disclosure Information

In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity (planners and speakers/authors/discussants/moderators) has disclosed all financial relationships with any commercial interest (termed by the ACCME as "ineligible companies", defined below) held in the last 24 months (see below for definitions). Please note that first authors were required to collect and submit disclosure information on behalf all other authors/contributors, if applicable.

Ineligible Company: The ACCME defines an "ineligible company" as any entity producing, marketing, re-selling, or distributing health care goods or services used on or consumed by patients. Providers of clinical services directly to patients are NOT included in this definition.

Financial Relationships: Relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.

Conflict of Interest: Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias during the session. Any conflicts noted below have been managed to our satisfaction. The disclosure information is intended to identify any commercial relationships and allow learners to form their own judgments. However, if you perceive a bias during the educational activity, please report it on the evaluation.

AUTHORS/CONTRIBUTORS

PRIMUM GROUP disclosures: Joseph R. Hsu, Stryker/Deputy Synthies/Globas, Consulting Fee/Consulting Fee/Consulting Fee, Consultant/Consultant/Consultant; Daniel Leas, Restor3d, Consulting Fee, Consultant; Michael Runyon, Abbott Diagnostics/Ortho Clinical Diagnostics, Grant/Grant, PI/PI. Shakira W. Burton, Christina Riojas, Gail Gesin, Charlotte B. Smith, Vashti Bandy, Ronald Sing, Tamar Roomian, Meghan K. Wally, Cynthia W. Lauer, Michael Beuhler, Michael J. Bosse, Jay Doucet, Michael Gibbs, Christopher Griggs, Steven Jarrett, Susan Odum, Animita Saha, Babak Sarani, Rachel B. Seymour, D. Matthew Sullivan, Brad Watling, Stephen Wyatt, Ziqing Yu have nothing to disclose.

EDITORIAL BOARD MEMBERS

First Name	Last Name	Disclosure?	Name of Commercial Interest	What was Received?	What was the Role?
Michael	Nance	Yes	Endo Pharmaceuticals	Consulting fee	Consultant
Heena	Santry	Yes	NBBJ	Salary	Employee
Jose	Diaz	Yes	Acumed/Acute Innovations	Consulting fee	Consultant
Lena	Napolitano	Yes	Merck Global Negative Advisory Board/Abbvie Critical Care Working Group	Consulting fee	Advisor/Consultant

Roxie Albrecht, Walter Biffel, Karen Brasel, Clay Cothren Burlew, Raul Coimbra, Todd Costantini, Rochelle Dicker, Tabitha Garwe, Kenji Inaba, Rosemary Kozar, David Livingston, Ali Salim, Deborah Stein, Alex Valadka, Robert Winchell, Bishop L. Zakhary, and Ben Zarrau have no disclosures or conflicts of interest to report. The Editorial Office staff has no disclosures to report.

Claiming Credit

To claim credit, please visit the AAST website at <http://www.aast.org/> and click on the "e-Learning/MOC" tab. You must read the article, successfully complete the post-test and evaluation. Your CME certificate will be available immediately upon receiving a passing score of 75% or higher on the post-test. Post-tests receiving a score of below 75% will require a retake of the test to receive credit.

Credits can only be claimed online

Cost

For AAST members and *Journal of Trauma and Acute Care Surgery* subscribers there is no charge to participate in this activity. For those who are not a member or subscriber, the cost for each credit is \$25.

Questions

If you have any questions, please contact AAST at 800-789-4006. Paper test and evaluations will not be accepted.

BACKGROUND:	Rib fractures are common in trauma patients and are associated with significant morbidity and mortality. Adequate analgesia is essential to avoid the complications associated with rib fractures. Opioids are frequently used for analgesia in these patients. This study compared the effect of a multimodal pain regimen (MMPR) on inpatient opioid use and outpatient opioid prescribing practices in adult trauma patients with rib fractures.
STUDY DESIGN:	A pre-post cohort study of adult trauma patients with rib fractures was conducted at a Level I trauma center before (PRE) and after (POST) implementation of an MMPR. Patients on long-acting opioids before admission and those on continuous opioid infusions were excluded. Primary outcomes were oral opioid administration during the first 5 days of hospitalization and opioids prescribed at discharge. Opioid data were converted to morphine milligram equivalents (MMEs).
RESULTS:	Six hundred fifty-three patients met inclusion criteria (323 PRE, 330 POST). There was a significant reduction in the daily MME during the second through fifth days of hospitalization; and the average inpatient MME over the first five inpatient days (23 MME PRE vs. 17 MME POST, $p = 0.0087$). There was a significant reduction in the total outpatient MME prescribed upon discharge (322 MME PRE vs. 225 MME POST, $p = 0.006$).
CONCLUSION:	The implementation of an MMPR in patients with rib fractures resulted in significant reduction in inpatient opioid consumption and was associated with a reduction in the quantity of opiates prescribed at discharge. (<i>J Trauma Acute Care Surg.</i> 2022;92:588–596. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)
LEVEL OF EVIDENCE:	Therapeutic/Care Management; level IV.
KEY WORDS:	Opioid; prescribing; multimodal pain regimen.

Rib fractures are present in up to 10% of injured patients, frequently occurring in the setting of multisystem trauma. They are a major cause of acute and chronic pain, which can lead to decreased quality of life and delay in return to routine activities. Current management strategies rely on aggressive pain control, pulmonary hygiene, and early mobilization. Rib fractures are associated with a mortality rate of up to 10% and a complication rate of 13%, with pain contributing to the subsequent morbidity.¹ Almost half of complications are pulmonary, including atelectasis or lobar collapse, pneumonia, aspiration, pulmonary embolism, pleural effusions, and acute respiratory distress syndrome.² In addition, in a retrospective review, patients sustaining blunt trauma with moderate to severe rib cage injuries were associated with higher rates of reevaluation and readmission.³ Pain control in these patients is an often complex and challenging endeavor, and yet is essential to enhance recovery, optimize pulmonary hygiene, and mitigate the worsening sequelae of disease.

Opioid analgesics remain the mainstay for pain management in patients with rib fractures despite multiple alternative analgesic options. In the United States, opioid prescriptions have nearly quadrupled from 1999 to 2014, without any measured difference in reported pain.⁴ Prescribing of opioids to opioid-naïve patients has been shown to increase chronic opioid use fivefold compared with patients who did not receive opioids.⁵ The increase in opioid pre-

scriptions has also been associated with a rapid rise in the number of drug overdoses. Opioid overdose is now the leading cause of injury-related death in over 30 states with more than 100 deaths per day in the United States.⁶

In an effort to address this epidemic, many institutions have implemented the use of a multimodal approach to pain control relying on nonopioid analgesics including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, skeletal muscle relaxants, alpha-2 agonists, mood stabilizers, neuropathic pain medications, including gabapentinoids, *N*-methyl-D-aspartate receptor antagonists, topical analgesics, as well as interventional therapies. Multimodal analgesia relies on synergistic combinations of medications to decrease dosing requirements and minimize adverse drug reactions for any single medication.⁷ In the setting of rib fractures, a multimodal approach has been suggested to address both pain control and respiratory performance.⁸ Numerous studies have addressed multimodal analgesia in the elective surgical patient population. Multimodal protocols have been less studied in the trauma population. The purpose of this study was to compare the effect of a multimodal pain regimen (MMPR) on inpatient opioid use and outpatient opioid prescribing practices in adult trauma patients with rib fractures.

METHODS

Patient Population

A retrospective cohort study was performed to detect differences before and after the implementation of a MMPR in accordance with STROBE guidelines (Supplemental Digital Content, <http://links.lww.com/TA/C254>). The institutional review board approved the study. Adult (≥ 18 years) patients admitted to Atrium Health Carolinas Medical Center with the diagnosis of rib fractures were eligible for inclusion in the analysis. Carolinas Medical Center is an American College of Surgeons-verified Level I trauma center located in Charlotte, North Carolina. Our trauma registry was queried to identify adult patients with rib fractures between July 2016 to December 2016 ("PRE," i.e., before protocol implementation) and July 2017 to December 2017 ("POST," i.e., after protocol implementation). Patients with current preadmission long-acting opioid medication use were excluded to minimize

Submitted: April 12, 2021, Revised: November 4, 2021, Accepted: November 6, 2021,
Published online: November 29, 2021.

From the Acute Care Surgery Division (S.W.B., C.R., C.B.S., V.B., C.W.L.), Atrium Health-Carolinas Medical Center; Division of Pharmacy (G.G.), FH Sammy Ross Trauma Center (R.S.), Atrium Health; Department of Orthopaedic Surgery (T.R., M.K.W., M.J.B., J.R.H., D.L., S.O., R.B.S., Z.Y.), Atrium Health Musculoskeletal Institute; NC Poison Control (M.B.), Department of Emergency Medicine (M.G., C.G., M.R.), Patient Safety (S.J.), Atrium Health; OrthoCarolina Research Institute (S.O.); Department of Internal Medicine (A.S.), Atrium Health Information and Analytic Services (D.M.S.), Atrium Health, Charlotte; GIV Hydration (B.W.), Huntersville; and Adult Psychiatry, Atrium Health (S.W.), Charlotte, NC. Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jtrauma.com).

Address for reprints: Meghan K. Wally, MSPH, PhD, Department of Orthopaedic Surgery, Atrium Health Musculoskeletal Institute, 1320 Scott Ave., Charlotte, NC 28204; email: Meghan.Wally@atriumhealth.org.

DOI: 10.1097/TA.00000000000003486

the impact of any preexisting opioid dependency. Patients on continuous opioid infusions were also excluded.

Multimodal Pain Regimen

A multidisciplinary committee of trauma surgeons and pharmacists designed and implemented an MMPR, including a pain control guideline and multimodal pain medication order set within the electronic health record in May 2017. Prior to the initiation of the MMPR, short- and long-acting opioids were first-line therapies in the adult pain management order set used to provide initial care. Long-acting opioids have been associated with increased risk of injury, addiction, and overdose and are no longer being used routinely. The MMPR implemented includes scheduled acetaminophen, ibuprofen, gabapentin, methocarbamol, and/or topical lidocaine as first-line agents (Fig. 1). A combination of short acting opioids in both intravenous (IV) and oral form are used as second-line options. These medications were ordered unless there were individual contraindications.

Data Collection and Outcomes

Patient demographics, including age, gender, Injury Severity Score (ISS), and chest (chest AIS) score were compared pre- and post-MMPR implementation. The primary outcome was inpatient opioid administration in morphine milligram equivalents (MMEs) during the first 5 days of hospitalization. Secondary outcomes included use of NSAIDs and gabapentinoids, frequency of receiving an opioid prescription at discharge, MME prescribed at discharge, hospital length of stay (LOS), need for intensive care unit (ICU) admission and ICU LOS, need for mechanical ventilation and duration of mechanical ventilation, incidence of acute kidney injury (AKI) and incidence of upper gastrointestinal bleeding

(UGIB). Inpatient opioid use was manually extracted from the electronic health record and converted to MMEs. The opioids prescribed on discharge were also recorded and converted to MME. To identify any increase in nonsteroidal anti-inflammatory complications, the incidence of AKI and UGIB was identified using existing fields in the trauma registry. In addition, a subset analysis was done on patients with isolated rib fractures, defined as greater than one rib fracture and an AIS score of 2 or less for areas outside the chest.

Data Analysis

Continuous variables were checked for normality graphically using histograms. Descriptive statistics were reported (counts and percentages for categorical variables, means and standard deviations for normally distributed continuous variables, medians and interquartile range (IQR) for nonnormal continuous variables).

We used control charts to assess changes in ISS, Glasgow Coma Scale (GCS) score, percent of patients that received a gabapentanoid, percent of patients that received an opioid in the hospital, the average MME, and the percent of patients that were prescribed an opioid at discharge over time.^{9,10} The pre-MMPR implementation period was used to calculate the center line and determine special cause variation in the postimplementation period. The July to December periods were originally chosen for the pre and post periods to account for seasonality differences that could have affected the intervention. Points that qualify for special cause variation (as specified per the Institute for Healthcare Improvement) have been highlighted in red.

Differences between patients pre- and post-MMPR were also assessed using χ^2 tests (Fisher's exact test in the case of small cell counts) for categorical variables. *t* Tests or Wilcoxon rank-sum tests were used for continuous normally or nonnormally

ADULT TRAUMA ADMISSION NON-CRITICAL CARE

Analgesics: Opioids

- ☐ Oxycodone
 - ☐ 2.5 mg oral q4h PRN **mild pain (1-3)**
 - ☐ 5 to 10 mg oral q4h PRN **moderate pain (4-7)**, see Order Comments (start at 5mg and if after 30 minutes pain score does not decrease by 1, may give additional 5mg. For subsequent doses, may provide 10mg if pain score 5 or greater. May provide for pain score greater than 7 if requested by patient in place of severe pain medication. Document request as a MAR comment. MAX 10mg q4hr.)
- ☐ ADULT PHARM PCA HYDROMORPHONE (SUB)*
- ☐ Hydromorphone
 - ☐ 0.25mg IV q2h PRN **moderate pain (4-7)**, see order comments (UNABLE TO TOLERATE ORAL MEDICATION: 2nd option if patient unable to tolerate oral medication. May provide for pain score greater than 7 if requested by patient in place of a severe pain medication. Document request as a MAR comment.)
 - ☐ 0.25 to 0.5 mg IV q2h PRN **severe pain (8-10)**, see order comments (start at 0.25mg and if after 30 minutes pain score does not decrease by 1, may give additional 0.25mg. For subsequent doses, may provide 0.5mg if pain score 8 or greater. MAX 0.5mg q2hr.)

Analgesics: Non-Opioids

NOTE TO PROVIDER: Select ONLY one nonsteroidal anti-inflammatory drug (NSAID)

- ☐ ibuprofen (USE WITH CAUTION IN PATIENTS ON NEPHROTOXIC MEDICATIONS)
 - 600 mg oral q6h, with food
 - 800 mg oral q6h, with food
- ☐ ketorolac
 - 30mg IV q6h x 5 days (weight 50kg or greater AND age less than 65 years)
 - 15mg IV q6h x 5 days (weight less than 50kg OR age 65 years or greater)
- ☐ acetaminophen (DO NOT COMBINE WITH OTHER ACETAMINOPHEN CONTAINING PRODUCTS)
 - 650mg oral q6h
 - 650mg rectal q6h
- ☐ gabapentin
 - 300mg oral q8h
- ☐ methocarbamol
 - 500mg oral q8h

Figure 1. Revised MMPR order set.

distributed data, respectively. For MME prescribed at discharge, a logarithmic transformation was applied prior to statistical analysis to achieve normality (descriptive statistics presented in tables and results are in original scale). SAS software version 9.4 was used for all analyses (SAS Institute Inc., Cary, NC). All statistical tests were two-tailed, and *p* values less than 0.05 were considered statistically significant.

RESULTS

During the study period, a total of 820 patients were assessed for eligibility based on presentation during either the PRE or POST study period with the presence of rib fractures. Mechanisms of injury were broad with the majority secondary to blunt trauma. One hundred sixty-seven patients were excluded; 158 for continuous opioid infusions and 9 for chronic opioid use prior to admission. A total of 653 patients (323 PRE, 330 POST) met inclusion criteria for review. Of note, four patients in the PRE group and five patients in the POST group were excluded from data collection for preadmission chronic opioid use. The majority of patients were male with approximately half of patients between 18 years and 55 years old (Table 1). The most common injury mechanisms were motor vehicle crash and falls, and the injury

TABLE 1. Patient Demographics and Clinical Outcomes Before and After MMMP Implementation

	Pre-MMMP, n = 323	Post-MMMP, n = 330	<i>p</i>
Male, n (%)	233 (72.1)	221 (67.0)	0.15
Age (y), n (%)			
18–55	180 (55.7)	159 (48.2)	0.11
56–65	57 (17.6)	60 (18.2)	
66+	86 (26.6)	111 (33.6)	
Mechanism of injury			0.56
Fall	84 (26.01)	104 (31.52)	
Motorcycle crash	38 (11.76)	33 (10.00)	
Motor vehicle crash	143 (44.27)	143 (43.33)	
Other	44 (13.62)	38 (11.52)	
Pedestrian struck	14 (4.33)	12 (3.64)	
ISS (median, IQR)	14 (9–19)	13 (9–17)	0.08
Chest AIS (median, IQR)	3 (2–3)	3 (2–3)	0.83
ED GCS score, median (IQR)	15 (15–15)	15 (15–15)	0.08
ED lactate, median (IQR)	1.99 (1.26–2.93)	1.89 (1.22–2.81)	0.50
Inpatient NSAID use, n (%)	240 (74.3)	225 (68.2)	0.08
Inpatient gabapentinoid use, n (%)	218 (67.5)	282 (85.5)	<.0001
Hospital LOS (d), median (IQR)	3 (2–6)	4 (2–7)	0.41
Admitted to ICU, n (%)	138 (42.7)	140 (42.4)	0.94
ICU LOS, median (IQR)	3 (2–4)	2 (2–4)	0.99
Mechanical ventilation, n (%)	32 (9.9)	22 (6.7)	0.13
Ventilator days, median (IQR)	2 (1–9)	2 (1–5)	0.48
Incidence of AKI, n (%)	3 (0.9)	1 (0.3)	0.63
Incidence of UGIB, n (%)	0 (0)	0 (0)	NA
Readmission, n (%)	4 (1.2)	4 (1.2)	1
Unplanned admission to ICU, n (%)	5 (1.6)	4 (1.2)	0.75
SBP (6 missing), mean (STD)	133 (26)	134 (25)	0.57
Shock Index (6 missing), median (IQR)	0.68 (0.56–0.79)	0.65 (0.55–0.78)	0.39




Figure 2. Control charts for percentage of patients receiving a gabapentinoid (A), average MME (B), and percentage of patients prescribed an opioid at discharge (C). Rules for special cause variation include the following: (1) 1 point outside 3-sigma limit; (2) 6 consecutive points increasing or decreasing; (3) 8 or more consecutive points above or below the centerline; (4) 2 of 3 points in the outer third; (5) hugging—15 points in the inner third. Special cause variation is shown in red.

mechanisms did not change significantly over the two periods. Although the specific concomitant injuries and number of rib fractures were not tracked in this study, the ISS and chest AIS score were not significantly different over the two periods. The admission lactate was also similar between the two periods. The hospital LOS, ICU admission rate, ICU LOS, rate of mechanical ventilation and number of ventilator days were unchanged after implementation of MMMP.

There was no evidence for special cause variation in the change in mean ISS or GCS score in the postimplementation period (Supplemental Fig. 1A–B, <http://links.lww.com/TA/C220>). Therefore, we did not adjust for ISS or GCS score when analyzing the other outcomes of interest. There was evidence for special cause variation for percent gabapentinoid prescribed (higher in the implementation period) (Fig. 2A). There was no evidence for special cause variation for the percent of patients receiving an opioid in the hospital. However, the two and three upper control limit lines cannot surpass 100%, which may have limited our ability for detection (Supplemental Fig. 1C, <http://links.lww.com/TA/C220>). Among patients prescribed inpatient opioids, there was evidence for special cause variation in the postimplementation period for average MME (decreased in postimplementation) (Fig. 2B). Finally, there was evidence for special cause variation for percent of patients prescribed an opioid at discharge (higher in the postimplementation period) (Fig. 2C).

Implementation of the MMMP reduced daily inpatient opioid administration during the first 5 days of hospitalization (23 MME PRE vs. 17 MME post, $p = 0.007$) (Table 2). There was a statistically significant increase in percentage of patients receiving inpatient opioids during their first five inpatient days after the MMMP implementation (291 patients, 90.1% PRE vs. 315, 95.5% POST, $p = 0.008$). However, there was a statically significant reduction in MME during each of Day 2 through Day 5 of hospitalization (Table 2). At the time of discharge, there was no significant difference in the number of patients prescribed opioids (196 patients, 60.7% PRE vs. 220 patients, 66.7% POST, $p = 0.11$) (Table 2). However, in patients who

TABLE 3. Patient Demographics and Clinical Outcomes Before and After MMMP Implementation in Patients With Isolated Rib Fractures (Extrathoracic AIS score ≤ 2)

	Pre-MMMP, n = 167	Post-MMMP, n = 201	p
Male, n (%)	116 (69.4)	135 (67.2)	0.64
Age (years), n (%)			
18–55	79 (47.3)	82 (40.8)	0.44
56–65	31 (18.6)	44 (21.9)	
66+	57 (34.1)	75 (37.3)	
ISS, median (IQR)	10 (9–14)	10 (9–14)	0.61
Chest AIS score, median (IQR)	3 (3–3)	3 (3–3)	0.36
Inpatient NSAID use, n (%)	136 (81.4)	149 (74.1)	0.09
Inpatient gabapentinoid use, n (%)	117 (70.1)	172 (85.6)	0.0003
Hospital LOS (d), median (IQR)	3 (2–4)	3 (2–5)	0.45
Admitted to ICU, n (%)	62 (37.1)	70 (34.8)	0.65
ICU LOS, median (IQR)	2 (2–4)	2 (2–3)	0.50
Mechanical ventilation, n (%)	8 (4.8)	5 (2.5)	0.23
Ventilator days, median (IQR)	2 (1–8)	3 (2–4)	0.51
Readmission, n (%)	2 (1.2)	3 (1.5)	1
Unplanned admission to ICU, n (%)	1 (0.6)	1 (0.5)	1

received opioids on discharge, there was a statistically significant reduction in the daily encounter MME (the daily quantity of opioids if taken as prescribed) for each prescription (median, 45; IQR, 30.0–54.9 PRE MME vs. median, 32.1; IQR, 24–49 POST MME; $p = 0.02$) (Table 2). There was a corresponding decrease in total MME prescribed after the implementation of the MMMP.

A subgroup analysis was conducted on patients admitted with isolated rib fractures (an extrathoracic AIS score of ≤ 2). Within this subset, there were a total of 368 patients (167 PRE vs. 201 POST). These patients were also mostly men, with a similar age distribution, and with similar ISS and chest AIS score before and after the MMMP implementation (Table 3). Similar to the overall group, the hospital LOS, ICU admission

TABLE 2. Patient Opioid Exposure Before and After MMMP Implementation

	Pre-MMMP	Post-MMMP	p
Patients who received inpatient opioids, n (%)	291 (90.1)	315 (95.5)	0.008
Inpatient MME, all patients			
Day 1 (n = 653), median (IQR)	12 (2–27)	10 (4–20)	0.91
Day 2 (n = 619), median (IQR)	30 (8–53)	21 (8–45)	0.004
Day 3 (n = 506), median (IQR)	30 (8–64)	19 (5–45)	0.0006
Day 4 (n = 415), median (IQR)	30 (8–62)	19 (4–38)	0.0001
Day 5 (n = 318), median (IQR)	30 (8–60)	15 (0–45)	0.004
Daily MME Administration over First 5 Hospital Days	23 (9–47)	17 (7–35)	0.007
Inpatient MME, patients who received any opioids during first 5 inpatient days			
Day 1 MME (n = 606), median (IQR)	14 (4–29)	11.50 (5–22)	0.28
Day 2 MME (n = 586), median (IQR)	32.5 (15–57)	22.50 (8–45)	0.0003
Day 3 MME (n = 484), median (IQR)	36 (9–68)	20.5 (7–45)	<0.0001
Day 4 MME (n = 402), median (IQR)	30 (14–64)	22.5 (5–38)	<0.0001
Day 5 MME (n = 145), median (IQR)	30 (8–60)	15 (0–45)	0.002
Patients prescribed opioids at discharge, n (%)	196 (60.7)	220 (66.7)	0.11
Total MME prescribed at discharge (n = 416), median (IQR)	322 (210–450)	225 (180–375)	0.007
Daily encounter MME prescribed at discharge (n = 416), median (Q1–Q3)	45 (30–55)	32.1 (24–49)	0.02

rate, ICU LOS, rate of mechanical ventilation and number of ventilator days were unchanged after implementation of MMMP. When comparing isolated rib fracture patients, there was no statistically significant change in the overall median MME received during the first 5 days of admission (18 PRE vs. 16 POST, $p = 0.11$). However, when patients who received no inpatient opioids on Day 1 through Day 5 were excluded, there was a statistically significant decrease in opioid consumption on inpatient Days 2 and 3 (Table 4). At the time of discharge, there was no difference in the frequency of opioids prescriptions between the two groups (111 patients, 66.5% PRE vs. 137 patients, 68.2% POST, $p = 0.73$). In this subgroup, there was a significant reduction in the total MME prescribed at discharge (median, 315.0; IQR, 210–488 MME PRE vs. median, 225; IQR, 180–375 MME POST; $p = 0.03$) (Table 4).

Although there was no effect on the use of NSAIDs, there was a statistically significant increase in use of gabapentinoids during the hospitalization after the initiation of the MMMP. In all rib fracture patients, there was a statistically significant increase in gabapentin after MMMP implementation (218, 67.5% PRE vs. 282, 85.5% POST; $p < 0.0001$) (Table 1). In the subgroup analysis of isolated rib fractures, there was also a statistically significant increase in gabapentinoid use (117, 70.1% PRE vs. 172, 85.6% POST; $p = 0.0003$) (Table 3). Of note, with the statistically significant increase in gabapentin use after the MMMP implementation, there were no changes in readmission or unplanned ICU admission rates.

DISCUSSION

In trauma patients with rib fractures, implementation of an MMMP significantly reduced inpatient opioid consumption and outpatient opioid prescriptions. While the use of NSAIDs was unchanged by the MMMP implementation, the use of gabapentinoids was significantly increased. This is one of only two studies to examine the effects of a MMMP on inpatient and outpatient opioid use in patients with rib fractures.

Management of pain in trauma patients with rib fractures requires a careful balance of providing relief of suffering and optimizing pulmonary performance to decrease complications while limiting the use of opioids and minimizing the side effects of nonopioid analgesics. The opioid epidemic has necessitated the development of alternative strategies to managing rib fracture pain. Multimodal pain regimens, regional and neuraxial analgesia, nonpharmacologic therapies, and operative stabilization have all been investigated as possible therapeutic interventions.

In the current study, we saw a significant increase in the use of gabapentin after the implementation of our MMMP. Gabapentin is a structural analog of γ -aminobutyric acid, although it does not appreciably interact with γ -aminobutyric acid receptors.¹¹ Gabapentin inhibits the $\alpha_2\delta$ subunit of voltage-gated calcium channels in the brain and reduces presynaptic release of excitatory neurotransmitters that are associated with pain perception.¹¹ Gabapentin is labeled for postherpetic neuralgia and is used in an off-label fashion for neuropathic, postoperative, and chronic pain.

Gabapentin is associated with neurologic and respiratory adverse drug reactions and requires dose reduction in the setting of renal impairment. In December 2019, the FDA¹² warned of serious, life-threatening, and fatal respiratory depression in patients receiving gabapentinoids. This risk may be increased with concomitant use of opioids and other central nervous system depressants, conditions such as chronic obstructive pulmonary disease, and in elderly patients. Furthermore, gabapentin misuse and withdrawal have been described and must be considered as potential complications, especially in at-risk populations.^{13,14} As a result of these potential risks, the use of gabapentin in patients with multisystem trauma should be done with caution.

While there are more studies investigating the use of gabapentin in surgical patients, there remains limited data on its benefit in the trauma population. A meta-analysis of preoperative gabapentin administration to patients in the setting of abdominal, orthopedic, gynecological, thyroid, breast, prostatectomy, caesarean section, and thoracotomy surgery was associated with lower postoperative opioid

TABLE 4. Patient Opioid Exposure Before and After MMMP Implementation in Isolated Rib Fractures

Isolated Rib Fractures (Extrathoracic AIS score ≤ 2)	Pre-MMP	Post-MMP	<i>p</i>
Patients who received inpatient opioids, n (%)	154 (92.2)	191 (95.0)	0.27
Inpatient MME, all patients			
Day 1 (n = 368), median (IQR)	10 (2–23)	10 (4–20)	0.61
Day 2 (n = 353), median (IQR)	23 (8–53)	23 (8–45)	0.19
Day 3 (n = 279), median (IQR)	30 (4–70)	15 (4–40)	0.013
Day 4 (n = 221), median (IQR)	25 (5–62)	18 (0–33)	0.013
Day 5 (n = 159), median (IQR)	23 (1–60)	15 (0–45)	0.08
Daily MME administration over first 5 hospital days	18 (8–46)	16 (7–33)	0.11
Inpatient MME, patients who received inpatient opioids			
Day 1 MME (n = 345), median (IQR)	12.5 (4–27)	11.5 (5–20)	0.97
Day 2 MME (n = 334), median (IQR)	26.5 (11–53)	22.5 (8–45)	0.09
Day 3 MME (n = 267), median (IQR)	30 (8–75)	18.1 (4–45)	0.005
Day 4 MME (n = 215), median (IQR)	28.8 (8–64)	20 (0–30)	0.008
Day 5 MME (n = 155), median (IQR)	22.5 (4–60)	15 (0–45)	0.07
Patients prescribed opioids at discharge, n (%)	111 (66.5)	137 (68.2)	0.73
Total MME prescribed at discharge (n = 248), median (Q1–Q3)	315.0 (210–488)	225.0 (180–375)	0.03
Daily encounter MME prescribed at discharge (n = 248), median (Q1–Q3)	45.0 (30–56)	32.1 (23–48)	0.13

use.¹⁵ However, in critically ill patients with rib fractures, there was no difference in numeric pain scores, oxygen requirement, or opioid consumption between gabapentin and placebo.¹⁶

Nonsteroidal anti-inflammatory drugs are another nonopioid analgesic option for managing trauma patients with rib fractures. Complications from NSAIDs are considerable and include gastrointestinal and renal adverse drug reactions. Gastrointestinal complications range from mild dyspepsia and heartburn to life threatening bleeding and perforation. Consistent use of NSAIDs for greater than 4 days is associated with increased risk of severe complications including bleeding, clinically significant ulceration and perforation.¹⁷ In our study, no cases of clinically significant upper gastrointestinal hemorrhage were identified either before or after implementation of the MMPR.

Nonsteroidal anti-inflammatory drugs decrease prostaglandin synthesis and, therefore, affect intraglomerular hemodynamics by decreasing the ability of the afferent arteriole to vasodilate.¹⁸ As, such, renal blood flow is altered. Nonsteroidal anti-inflammatory drugs are also associated with interstitial nephritis.¹⁸ Risk factors for drug-induced kidney disease include older age and chronic kidney disease, with a threefold to fourfold increased risk of worsening renal function for patients with abnormal baseline renal function who use ibuprofen.¹⁹ Given the advanced age of many patients with rib fractures, the risk of high-dose NSAID use remains significant. Despite 30% of our patients being older than 65 years, the rate of acute kidney injuries was low and remained unchanged by the implementation of the MMPR. However, it is possible that some of the adverse effects of NSAIDs may have been delayed and unrecognized on initial admission.

There have been conflicting results for the use of nonopioid analgesics in patients with rib fractures. Lidocaine patches have been shown to have minimal impact on pain control in a randomized controlled trial when compared with standard therapy.²⁰ However, some studies examining the effect of nonopioid medications in patients with rib fractures have demonstrated success in minimizing opioid use. In one small retrospective cohort study, scheduled IV ibuprofen was associated with decreased opioid use and decreased hospital LOS.²¹ Another retrospective cohort study showed that IV ketorolac was associated with a decreased incidence of pneumonia in patients with rib fractures.²² These studies did not explore the impact of a multimodal pain protocol on the quantity of opioids prescribed at the time of discharge. In addition, the studies did not evaluate the effect of multimodal regimens on adverse drug reactions, including stress ulcer bleeding and acute kidney injury, or polypharmacy effects, such as unplanned ICU admission.

While the effects of MMPRs in elective surgical patients has been well documented, their impact in trauma patients is less clear. Several studies note decreased opioid usage after implementation of a multimodal regimen. In a recent retrospective study of more than 6000 trauma patients over an 8-year period, the authors found a significant reduction in inpatient opioid consumption as well as the quantity of outpatient opioid prescriptions in patients with at least one rib fracture.²³ While this is the only study to date to examine the effect of a MMPR on inpatient and outpatient opioid use in rib fracture patients, this study does have notable limiting factors. At the start of the study, the opioid epidemic came into national focus, substantially changing the culture regarding opioid use, resulting in both providers and patients having

a better understanding of the dangers of opioid use. Thus, provider and patient awareness regarding the opioid epidemic were likely a significant confounding factor that may have obscured the true impact of a multimodal regimen on inpatient and outpatient opioid use in that study. In addition, scheduled tramadol, an opioid derivative, was used as part of the MMPR in this study, raising concerns for the significant opioid exposure in the MMPR itself, which may have increased the total inpatient MME requirement. Indeed, the outpatient prescription rate of tramadol increased significantly during the duration of the study. This would not only expose patients to the risk of tramadol addiction, abuse, and misuse, but also to other adverse effects specified in the US Boxed Warning for this agent.²⁴ These include, but are not limited to, life-threatening respiratory depression, complex effects resulting from interactions with drugs affecting cytochrome P450 isoenzymes, and potential for profound sedation, coma, and death when used concomitantly with benzodiazepines or other CNS depressants.

In a smaller retrospective cohort study of critically ill trauma patients, the authors found a significant decrease in inpatient opioid use following MMPR implementation.²⁵ In addition, they found a corresponding decrease in inpatient opioid consumption with each successive number of pharmaceutical adjuncts used. Interestingly, Hamrick et al.²⁵ also found that a majority of patients were prescribed a higher daily opioid dose on discharge than they had used during the preceding 24 hours of hospitalization, suggesting opportunities for customizing prescriptions to more closely match inpatient opioid requirements. However, this study was a small heterogeneous group of multiple trauma patients, which represents quite a variable spectrum. There was a significant difference in injury mechanisms pre and post multimodal regimen implementation. The researchers also compared periods 2 years apart, which again raises the possibility that changes in patient and provider awareness of the growing opioid epidemic during the study, distorted the actual impact of the multimodal regimen.

In the current retrospective study, we evaluated a brief period before and after the implementation of an MMPR to minimize the impact of changes in provider and patient perspective over the course of the study. Like the previous retrospective studies, we did see a statistically significant reduction in the quantity of opioids administered during the inpatient setting for multiple trauma patients with rib fractures. However, we did not observe the same reduction in inpatient opioid consumption in patients with isolated rib fractures. We did see a reduction of inpatient MME for Days 2 and 3 in isolated rib fracture patients who required inpatient opioids. It is unclear whether the lack of a statistical difference in the inpatient MME of this subgroup was related to an overall lower injury burden, as suggested by the lower ISS, and thus decreased opioid requirements, or the lower power of this subset analysis. Notably, after the implementation of the MMPR, there was no change in NSAID use, suggesting that some individual elements of MMPR were already being used prior to the protocol. There was a statistically significant increase in gabapentin use after the implementation of the protocol, which may have contributed to the reduction in the opioid consumption during the study period. However, we cannot conclude that this alone was responsible for the reduction in MME. Consideration must also be given to the risk-benefit profile of this agent, and its place in pain management closely scrutinized given its potential for adverse drug reactions. There was a significant decrease in the MME

prescribed at discharge to patients after implementation of the MMPR, although no difference was seen in percentile of patients prescribed opioids on discharge. This was also true for the subset of isolated rib fracture patients.

Limitations of this study include its retrospective design. While exposure to NSAIDs and gabapentin were assessed, dosing strategies and adherence to the MMPR were not. We also do not have data regarding the use of neuraxial or regional anesthesia techniques or surgical stabilization of the rib fractures in our patient population, which may impact the inpatient and outpatient opioid requirement. However, given the stability of our performance of regional anesthesia and surgical stabilization over time, as well as their use in the minority of our total rib fracture patients, the effect on our outcomes is likely to be relatively small. Given the variable reasons for opioid infusions for mechanically ventilated patients other than pain control, patients requiring opioid infusions were excluded. In addition, this exclusion likely eliminated some of the moderate traumatic brain injury (TBI) patients and all severe TBI patients as these patients were intubated and supported with opioid infusions as part of their TBI therapy. This occurrence can be seen in the median admission GCS score of 15 in both PRE and POST groups. This exclusion eliminated the falsely low estimate of oral opioid consumption in these patients, but also excluded many of the more severely injured patients. This exclusion did minimize the effect of TBI on the perception and management of rib fracture pain. Another limitation of our study is the lack of information on number of ribs fractured and characteristics of the rib fractures. While this information was beyond the scope of our review, we do know that the chest AIS score was similar PRE and POST MMPR, suggesting no significant change in the severity of the chest injuries over the study period. Lastly, the development of the MMPR at our institution was largely in response to the growing opioid epidemic. It is possible that providers' attitudes regarding opioid prescriptions changed during the study period and that this contributed to the observed decrease in outpatient opioid prescriptions. The majority of inpatient orders and discharge prescriptions were written by rotating residents and trauma advanced practice providers. Although the use of the MMPR order set was advised and encouraged, rotating personnel could have contributed to variability in compliance with the use of the order set. While the Hawthorne effect could be responsible for some participant bias and enhanced compliance with MMPR order set usage, this effect on provider behavior was likely modest given the frequent order set modifications and guideline development within our trauma program. Since the MMPR order set was imbedded within our trauma admission order sets, its use was likely robust as it became the least labor-intensive method to enter orders, including pain medication. It is also unclear if the North Carolina Strengthen Opioid Misuse Prevention Act legislation, passed in 2017, had any impact on our results.²⁶ This legislation limits opioid prescriptions to a 5-day supply after injury or trauma and 7-day supply after surgical procedures. One might postulate that the decrease in inpatient opioid use and outpatient prescriptions were due to this legislation, the implementation of this MMPR, or a combination of both.

The impact of the opioid epidemic cannot be overstated. While we search to find solutions to minimize opioid consumption, we must also refrain from overly optimistic, simplistic solutions

without evidence of their effectiveness. Multimodal pain regimens have become a common solution to minimize opioid consumption in most trauma centers, despite minimal evidence of the effectiveness in doing so. When establishing guidelines and protocols, as important as the implementation phase is the subsequent review of the effectiveness. Adherence to and assessment of outcomes after a new guideline has been implemented is crucial to a strong performance improvement program. Our intent was to review an institutional performance improvement initiative in the form of an MMPR. In our review, we have concluded that our MMPR did result in a statistically significant reduction in both inpatient opioid consumption and outpatient prescription quantity. In addition to continued use of the MMPR, we will continue to search for which combinations of which medications are the most effective and to find mechanisms to mirror an outpatient prescription with a patient's inpatient opioid requirement. It is unknown whether these results are generalizable beyond Level I trauma centers or at other hospitals or regions with different ongoing interventions or legislation surrounding opioid prescribing. Next steps should include dissemination of this intervention to other settings to determine generalizability.

In trauma patients with rib fractures, implementation of an MMPR significantly reduced inpatient opioid consumption and outpatient opioid prescriptions. We are witnessing an advance in the use of various nonopioid analgesics, as well as procedural techniques to aid in the treatment of pain. Future efforts will likely be directed at expanding regional and neuraxial analgesia techniques, nonpharmaceutical adjunct usage, and developing a tool to determine the appropriate quantity of opioids for discharge, using the patient's inpatient requirement as a guide. With a growing number of options now available for pain control, it is crucial to determine which methods, and in which combinations, are most effective at reducing pain, with the least complications and in the most cost effective way, as we continue to treat rib fractures in trauma patients.

AUTHORSHIP

S.W.B. contributed to the study conception and design, acquisition of data, and drafting of the article. C.R. contributed to the study conception and design, acquisition of data, and drafting of the article. G.G. contributed to the acquisition of data and drafting of the article. C.B.S. contributed to the acquisition of data and drafting of the article. V.B. contributed to the acquisition of data and the drafting of the article. R.S. contributed to the study conception and design and the drafting of the article. T.R. contributed to the analysis and interpretation of data and drafting of the article. M.K.W. contributed to the acquisition of data, analysis and interpretation of data, and drafting of the article. C.W.L. contributed to the study conception and design, acquisition of data, analysis and interpretation of data, and drafting of the article. The PRIMUM Group contributed to the study conception and design, acquisition of data, and critical revision.

PRIMUM Group: Michael Beuhler, MD, Michael J. Bosse, MD, Jay Doucet, MD, MSc, Michael Gibbs, MD, Christopher Griggs, MD, Joseph R. Hsu, MD, Steven Jarrett, PharmD, Daniel Leas, MD, Susan Odum, PhD, Michael Runyon, MD, Animita Saha, MD, Babak Sarani, MD, Rachel B. Seymour, PhD, D. Matthew Sullivan, MD, Brad Watling, MD, Stephen Wyatt, MD, and Ziqing Yu, MS.

DISCLOSURE

This work was supported in part by a cooperative agreement (CE14-004 Award Number CE002520) from the Centers for Disease Control and Prevention and by an internal grant from the Carolinas Trauma Network Research Center of Excellence. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

Conflicts of Interest: M.B. reports stock ownership in an orthopedic implant company and a grant from the DOD. C.G. reports American College of Emergency Physicians board membership and payment from Boston University for preparation of pain management and opioid prescribing. D.L. reports consultancy for Restor3d and ownership in Pressio. J.R.H. reports consultancy for Globus Medical and personal fees from Smith & Nephew speakers' bureau. M.R. reports research funding from Abbott Laboratories and Bristol-Myers Squibb. All other authors declare no conflicts of interest.

REFERENCES

1. Fligel BT, Luchette FA, Reed RL, Esposito TJ, Davis KA, Santaniello JM, Gamelli RL. Half-a-dozen ribs: the breakpoint for mortality. *Surgery*. 2005; 138:717–723;discussion 723–5.
2. Ziegler DW, Agarwal NN. The morbidity and mortality of rib fractures. *J Trauma*. 1994;37:975–979.
3. Baker JE, Skinner M, Heh V, Pritts TA, Goodman MD, Millar DA, Janowak CF. Readmission rates and associated factors following rib cage injury. *J Trauma Acute Care Surg*. 2019;87(6):1269–1276.
4. Hedegaard H, Warner M, Miniño AM. Drug overdose deaths in the United States, 1999–2016. *NCHS Data Brief*. 2017;1–8.
5. Calcaterra SL, Yamashita TE, Min SJ, Keniston A, Frank JW, Binswanger IA. Opioid prescribing at hospital discharge contributes to chronic opioid use. *J Gen Intern Med*. 2016;31:478–485.
6. CDC/NCHS, national Vital Statistics System, Mortality. *CDC Wonder*. Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
7. Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, et al. Management of postoperative pain: a clinical practice guideline from the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain*. 2016;17: 131–157.
8. Witt CE, Bulger EM. Comprehensive approach to the management of the patient with multiple rib fractures: a review and introduction of a bundled rib fracture management protocol. *Trauma Surg Acute Care Open*. 2017;2(1): e000064.
9. Benneyan JC. Statistical quality control methods in infection control and hospital epidemiology, part I: introduction and basic theory. *Infect Control Hosp Epidemiol*. 1998;19(3):194–214.
10. Benneyan JC. Statistical quality control methods in infection control and hospital epidemiology, part II: chart use, statistical properties, and research issues. *Infect Control Hosp Epidemiol*. 1998;19(4):265–283.
11. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and $\alpha 2 \delta$ -1 calcium channel subunit in neuropathic pain. *Pharmacol Res Perspect*. 2016; 4(2):e00205.
12. FDA Safety Alert. MedWatch. FDA warns about serious breathing problems with seizure and nerve pain medications (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). Food and Drug Administration Website. Available at: <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin>. Published December 19, 2019. Accessed June 22, 2020.
13. Mersfelder TL, Nichols WH. Gabapentin: abuse, dependence, and withdrawal. *Ann Pharmacother*. 2016;50(3):229–223.
14. Mah L, Hart M. Gabapentin withdrawal: case report in an older adult and review of the literature. *J Am Geriatr Soc*. 2013;61(9):1635–1637.
15. Arumugam S, Lau CS, Chamberlain RS. Use of preoperative gabapentin significantly reduces postoperative opioid consumption: a meta-analysis. *J Pain Res*. 2016;9:631–640.
16. Moskowitz EE, Garabedian L, Hardin K, Perkins-Pride E, Asfaw M, Preslaski C, Leasia KN, Lawless R, Burlew CC, Pieracci F. A double-blind, randomized controlled trial of gabapentin vs. Placebo for acute pain management in critically ill patients with rib fractures. *Injury*. 2018;49(9): 1693–1698.
17. Ofman JJ, MacLean CH, Straus WL, Morton SC, Berger ML, Roth EA, Shekelle P. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. *J Rheumatol*. 2002;29:804–812.
18. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. *Crit Care Med*. 2010;38:S169–S174.
19. Murray MD, Brater DC, Tierney WM, Hui SL, McDonald CJ. Ibuprofen-associated renal impairment in a large general internal medicine practice. *Am J Med Sci*. 1990;299(4):222–229.
20. Ingalls NK, Horton ZA, Bettendorf M, Frye I, Rodriguez C. Randomized, double-blind, placebo-controlled trial using lidocaine patch 5% in traumatic rib fractures. *J Am Coll Surg*. 2010;210(2):205–209.
21. Bayouth L, Safcsak K, Cheatham ML, Smith CP, Birrer KL, Promes JT. Early intravenous ibuprofen decreases narcotic requirement and length of stay after traumatic rib fracture. *Am Surg*. 2013;79:1207–1212.
22. Yang Y, Young JB, Schermer CR, Utter GH. Use of ketorolac is associated with decreased pneumonia following rib fractures. *Am J Surg*. 2014;207: 566–572.
23. Wei S, Green C, Truong VTT, Howell J, Ugarte SM, Albarado R, Taub EA, Meyer DE, Adams SD, McNutt MK. Implementation of a multi-modal pain regimen to decrease inpatient opioid exposure after injury. *Am J Surg*. 2019; 218(6):1122–1127.
24. *Ultram* [package insert]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019.
25. Hamrick KL, Beyer CA, Lee JA, Cocanour CS, Doby JJ. Multimodal analgesia and opioid use in critically ill trauma patients. *J Am Coll Surg*. 2019; 228(5):769–775.e1.
26. Strengthen Opioid Misuse Prevention Act of 2017. Session law 2017-74, House Bill 243.